25 June 2019 - - The Center for Diabetes Technology of the University of Virginia has licensed US-based digital health technology company Klue's software for a planned clinical trial, Klue said.
The UVA CDT, a recognised world leader in the research of diabetes, has pursued a path to advance the use of technology, including the development of decision support and automated insulin delivery systems, to improve management, monitoring, and therapies for patients with Type 1 Diabetes.
The UVA Center for Diabetes Technology is licensing Klue's patented gesture sensing and behavioral analytics software and will be validating Klue's mealtime insulin reminder application in a 12-week randomised clinical trial.
The study has received IRB approval and is currently enrolling patients.
With this clinical trial, the CDT and Klue aim to deepen the scientific understanding of how automatic meal detection combined with real-time signaling can reduce the daily burden on patients with type 1 diabetes, improve adherence to mealtime insulin bolusing and improve glycemic control.
Klue's patented motor artificial intelligence technology reduces eating and drinking behaviors from analyzing a user's wrist movements.
Non-intrusive and automatic, the detection happens in real time, making it possible, for the very first time, to act on the knowledge of eating happening without any manual action by the user and long before blood sugar levels start to rise.
Klue empowers companies and organizations across the health spectrum with actionable insights and delightful patient experiences that enable groundbreaking solutions, kindle new business models and pave the way to better health.
Klue is a digital health technology company developing an operating system for behaviour change and real-time digital therapeutics. Initially focused on the ability to detect when and how a user eats and drinks, Klue is building a platform that elevates the more important consumption patterns and acts "in-the-moment" when the impact is the biggest.